Insider Trading Alert - CLF, AEGN And SGEN Traded By Insiders
Friday, Nov. 6, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $473.82 to $10,527,076.00.
Highlighted Stocks Traded by Insiders:
Cliffs Natural Resources (CLF) - FREE Research Report
Sawyer James S, who is Director at Cliffs Natural Resources, bought 25,000 shares at $3.07 on Nov. 6, 2015. Following this transaction, the Director owned 34,682 shares meaning that the stake was boosted by 258.21% with the 25,000-share transaction.
The shares most recently traded at $3.14, up $0.07, or 2.23% since the insider transaction. Historical insider transactions for Cliffs Natural Resources go as follows:
- 4-Week # shares bought: 23,015
- 4-Week # shares sold: 15,000
- 12-Week # shares bought: 23,015
- 12-Week # shares sold: 15,000
- 24-Week # shares bought: 23,015
- 24-Week # shares sold: 15,000
The average volume for Cliffs Natural Resources has been 5.1 million shares per day over the past 30 days. Cliffs Natural Resources has a market cap of $434.2 million and is part of the basic materials sector and metals & mining industry. Shares are down 55.88% year-to-date as of the close of trading on Friday.
Cliffs Natural Resources Inc., a mining and natural resources company, produces iron ore and metallurgical coal. The stock currently has a dividend yield of 10.22%. Currently, there is 1 analyst who rates Cliffs Natural Resources a buy, 4 analysts rate it a sell, and 8 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on CLF - FREE
rates Cliffs Natural Resources as a
. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, poor profit margins and weak operating cash flow. Get the full
Cliffs Natural Resources Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Aegion (AEGN) - FREE Research Report
White Michael D, who is SVP & Corporate Controller at Aegion, sold 451 shares at $20.76 on Nov. 6, 2015. Following this transaction, the SVP & Corporate Controller owned 10,601 shares meaning that the stake was reduced by 4.08% with the 451-share transaction.
The shares most recently traded at $21.27, up $0.51, or 2.4% since the insider transaction. Historical insider transactions for Aegion go as follows:
- 4-Week # shares bought: 238
- 4-Week # shares sold: 4,000
- 12-Week # shares bought: 238
- 12-Week # shares sold: 4,000
- 24-Week # shares bought: 238
- 24-Week # shares sold: 4,000
The average volume for Aegion has been 191,200 shares per day over the past 30 days. Aegion has a market cap of $767.7 million and is part of the industrial goods sector and materials & construction industry. Shares are up 17.84% year-to-date as of the close of trading on Friday.
Aegion Corporation engages in the research and development, manufacture, maintenance, construction, installation, coating and insulation, cathodic protection, distribution, and licensing of proprietary technologies and services for the protection and maintenance of infrastructure worldwide. The company has a P/E ratio of 13.8. Currently, there is 1 analyst who rates Aegion a buy, no analysts rate it a sell, and 4 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on AEGN - FREE
rates Aegion as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and poor profit margins. Get the full
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Seattle Genetics (SGEN) - FREE Research Report
Dobmeier Eric, who is Chief Operating Officer at Seattle Genetics, sold 17,452 shares at $42.50 on Nov. 6, 2015. Following this transaction, the Chief Operating Officer owned 80,888 shares meaning that the stake was reduced by 17.75% with the 17,452-share transaction.
The shares most recently traded at $44.06, up $1.56, or 3.54% since the insider transaction. Historical insider transactions for Seattle Genetics go as follows:
- 4-Week # shares sold: 10,000
- 12-Week # shares sold: 10,000
- 24-Week # shares sold: 10,000
The average volume for Seattle Genetics has been 1.1 million shares per day over the past 30 days. Seattle Genetics has a market cap of $6.1 billion and is part of the health care sector and drugs industry. Shares are up 33.89% year-to-date as of the close of trading on Friday.
Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. Currently, there are 4 analysts who rate Seattle Genetics a buy, no analysts rate it a sell, and 5 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on SGEN - FREE
rates Seattle Genetics as a
. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full
Seattle Genetics Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.